Our GLP-1 Daily Support is designed to provide the nutrients your body needs while your appetite is reduced, and Weight Loss Boost can help support energy levels
The SOUL trial (2025), a large-scale, double-blind, placebo-controlled study, evaluated once-daily oral semaglutide in 9,650 patients with T2DM and established atherosclerotic cardiovascular disease, chronic kidney disease, or both
Effect of high pressure processing on the survival of Salmonella enteritidis and shelf-life of chicken fillets
Advances in Neurobiology, 13, 197-232
Glucagon receptor activation is driving meaningful thermogenesis
On the Cagrilintide side, the value of the standalone phase 2 trial is that it isolates the amylin effect from any GLP-1 contribution